Mankind Pharma invests in Actimed Therapeutics to support the latter’s development of treatment for cancer cachexia. On 23 January 2023, Mankind Pharma announced its move to invest in the UK-based clinical-stage specialty pharma company Actimed Therapeutics. Actimed could effectively close its second and final tranche of seed financing through this investment. (Pharma News – 23.01.2023) […]
On 4 February 2023, Lupin announced the recall of Clobetasol propionate cream over quality issues. As per the USFDA [1], the pharma major recalled 5,720 tubes of Clobetasol propionate cream from the U.S. market due to its poor quality. This cream is indicated for use in various skin conditions like dermatitis, eczema, and psoriasis. The recalled tubes
Lupin issues nationwide recall of Clobetasol propionate cream. Read More »
The USFDA[1] has revealed that Global Pharma Healthcare recalls all the batches of artificial tears lubricant eye drops from the US market. These eye drops were distributed by EziCare, LLC, and Delsam Pharma to the consumers. The recent move was taken due to the possible contamination of these lots. Global Pharma Healthcare recalls Artificial Tears
Global Pharma Healthcare recalls Artificial Tears Lubricant eye drops. Read More »
Cancer research and discovery is the process of uncovering new information about cancer and how it can be treated. This research is conducted by medical researchers, biologists, and other experts who seek to understand cancer’s causes, development, and potential treatments. Cancer research and discovery can involve laboratory experiments, clinical trials, and epidemiological studies. Research is
USFDA issues OAI notice for Torrent Pharma’s Indrad facility in Gujarat.In response to this notice, Torrent Pharma has clarified that it will not impact this facility’s existing supplies or revenues. (OAI notice for Torrent Pharma) This manufacturing facility produces formulations and active pharmaceutical ingredients (API) with an annual capacity of 30 million vials. The pharma
On 23 January 2023, Mankind Pharma announced its move to invest in the UK-based clinical-stage specialty pharma company Actimed Therapeutics. Actimed could effectively close its second and final tranche of seed financing through this investment. Actimed has also revealed that it is developing a lead asset, S-pindolol, for treating cancer cachexia. In context to this
Cancer Cachexia: Mankind Pharma’s association with Actimed Therapeutics Read More »
Aculys Pharma and Four H have announced a research collaboration to explore the potential of wearable devices to improve clinical trial outcomes. The partnership will combine Aculys’ proprietary data analytics platform with Four H’s wearable device technology to better understand and predict patient behaviors, such as adherence to medication regimens and symptom tracking. The collaboration
Zydus receives USFDA’a approval for marketing its epilepsy and menopause drugs. Pharma news- On 2 December 2022, Zydus received the USFDA’s[1] green signal to market Estradiol Transdermal System, USP[2] in the U.S. market. The approved formulations are 0.025mg/day, 0.0375 mg/day, 0.05 mg/day, 0.075 mg/day, and 0.1 mg/day estradiol transdermal systems. This drug is indicated for
GC Pharma and Tottori University have collaborated to accelerate the global development of the chaperone therapy of GM1 gangliosidosis (GM1). Per this agreement, GC Pharma has obtained the exclusive rights to develop and commercialize the therapy worldwide and the responsibility to conduct clinical trials. At the same time, Tottori is entitled to receive an upfront
pharma News July 2021: Let us know what’s happening around the globe and the Indian Pharma Industry. Three-dose ZyCoV-D vaccine could be just two doses, says pharma firm Zydus Cadila pharma News July 2021: 1 July 2021 Zydus has announced that the immunogenicity produced by the two-dose regimen of ZyCoV – D vaccine (3 mg
